Replies to post #171376 on Avid Bioservices Inc (CDMO)

[biopharm]

MDSC's : Auto-Immune Diseases : Type I Diabetes

No wonder why a partnership can't be inked....

Mr King, hold on... don't sign just yet! We need $500M more to get more clinical trials initiated, I think I know what you mean by that "astronomical" word now.

Role of myeloid-derived suppressor cells in type 1 diabetes

Adoptive transfer of MDSCs reduced diabetes by 75% compared with control group

http://www.jimmunol.org/cgi/content/meeting_abstract/186/1_MeetingAbstracts/167.16

Does everyone realize how many hundreds of trials will be initiated with Bavituximab and PS targeting ? I am stunned at how afraid? analysts are for not taking the plunge and staying ahead of the curve.

[biopharm]

Peregrine KOL : Dmitry Gabrilovich : April 10 at NYU

Start Date/Time: 4/10/2014 12:00 PM

End Date/Time: 4/10/2014 1:00 PM

Sponsored by: Immunology Club

Seminars: Regulating the fate of myeloid-derived suppressor cells in cancer

Speaker: Dmitry I. Gabrilovich, M.D., Ph.D.

Speaker Institution: The Wistar Institute, University of Pennsylvania

http://calendar.med.nyu.edu/index.cfm?fuseaction=somcalendar.ShowEvent&UsePopUpWindowForShowEvent=TRUE&CurrentDate=04/10/2014&fusecalendar_ID=78778

---------------------------------------------------------

Another non-PPHM event.... though strengthening the MOA of PS Targeting and slowly getting the word out to Medical Schools..etc... its a direct PPHM event, since we are talking MDSC's that directly relates to targeting flipped-PS